Cytotrait
Cytotrait50
About
What does Cytotrait do?
Cytotrait is a biotechnology spinout from the University of Manchester that utilizes its proprietary Mutant Organelle Selection System (MOSS) to precisely edit chloroplast and mitochondrial genomes in plants. This technology enables the development of crops with enhanced yield, resilience, and new food traits, while potentially streamlining regulatory pathways compared to conventional nuclear genome engineering.
What is Cytotrait's valuation?
StartupHub estimates Cytotrait's effective valuation at $12.0M (range $7.5M to $18.0M, 20% confidence), based on comparable companies in the sector.
How much funding has Cytotrait raised?
Cytotrait has raised a total of $3M in funding. The most recent round on record is Seed.
Where is Cytotrait headquartered?
Cytotrait is headquartered in Manchester, United Kingdom.
When was Cytotrait founded?
Cytotrait was founded in 2026.
What industry does Cytotrait operate in?
Cytotrait operates in Agriculture, Biotechnology, Gene Editing, Biotech, Agritech, Deep Tech.
How many employees does Cytotrait have?
Cytotrait has approximately 5 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.